CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 300 enrolled
Drug / intervention
Nitric Oxidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03661385
NCT03661385Phase 3Completed

A Randomised Controlled Trial of Nitric Oxide Administration During Cardiopulmonary Bypass in Infants Undergoing Arterial Switch Operation for Repair of Transposition of the Great Arteries

Murdoch Childrens Research Institute·interventional·Posted Sep 7, 2018·Updated Apr 18, 2024

In Brief

A Phase 3 clinical trial evaluating Nitric Oxide for Low Cardiac Output Syndrome and Transposition of Great Vessels. Completed, enrolled 300 participants across 4 sites in 4 countries.

Detailed Summary

This trial will test if adding nitric oxide (NO) gas to the cardiopulmonary bypass (CPB) circuit in infants undergoing an arterial switch operation (ASO) for Transposition of the Great Arteries (TGA) changes the incidence of major postoperative adverse events (AEs). Major postoperative AEs include cardiac arrest, emergency chest opening, use of ECMO (machine that acts as an artificial heart and lung during surgery), and death. Participants will be randomised to receive oxygen plus nitric oxide (intervention arm) or oxygen without nitric oxide (control arm) during CPB.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, Indonesia, Malaysia
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 7, 2018
Enrollment StartJul 11, 2018
Primary CompletionMar 23, 2022
Study CompletionApr 23, 2023
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.8 years ago

Interventions

Nitric Oxidedrug

Addition of nitric oxide 20ppm into bypass circuit